HER2-directed therapy is considered to be the gold standard of treatment for patients with HER2-positive breast cancer, and has been shown to improve responses and clinical outcomes compared with previous standard-of-care therapies (5–7). The gene discussed is ERBB2; the disease is breast carcinoma.